A Phase 3, Single Arm, Open Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women with Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk of Pregnancy
IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age, Version 1.0
Clinical research is one of the primary reasons the University of Colorado Anschutz Medical Campus is a nationally renowned healthcare destination. Yet in 2019, only 25% of CU Anschutz adult clinical trials enrolled even one participant over age 50. Study results may not apply to unrepresented populations, so the National Institutes of Health (NIH) requires clinical research to include individuals across the life span.